| pubmed-article:8620919 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C0270611 | lld:lifeskim |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C0917798 | lld:lifeskim |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C1704264 | lld:lifeskim |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C0205234 | lld:lifeskim |
| pubmed-article:8620919 | lifeskim:mentions | umls-concept:C0205100 | lld:lifeskim |
| pubmed-article:8620919 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8620919 | pubmed:dateCreated | 1996-6-18 | lld:pubmed |
| pubmed-article:8620919 | pubmed:abstractText | We assessed the efficacy of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) on brain injury and edema formation after permanent middle cerebral artery occlusion (MCAo) in the rat. Previous studies showed that low amounts of rhIL-1ra injected directly into the brain significantly decreased infarct size after MCAo or excitotoxic injury in rats. Peripheral administration of rhIL-1ra (100 mg/kg sc at 0, 4, 8, 12, and 18 h after MCAo) significantly inhibited infarct size, by 46% (P < 0.05), measured at 24h. This was greater than the effect of MK801 administered immediately after MCAo (4 mg/kg ip, 0 h) which did not significantly reduce infarct size. rhIL-1ra (100 mg/kg also significantly inhibited cerebral edema formation by 49% (p< 0.05 measured 24 h after MCAo, but did not reduce edema formation measured 2 h after MCAo, but did not reduce edema formation measured 2 h after MCAo. Inhibition of infarction by rhIL-1ra was dependent on dose and time of administration. Together the results demonstrate that peripherally administered rhIL-1ra at high doses is able to mimic the efficacy of low dose of rhIL-1ra administered directly into the brain in a rodent model of stroke and that protection observed with rhIL-1ra was better than that offered by MK801 in this model. | lld:pubmed |
| pubmed-article:8620919 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8620919 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8620919 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8620919 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8620919 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8620919 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8620919 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8620919 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8620919 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8620919 | pubmed:issn | 0014-4886 | lld:pubmed |
| pubmed-article:8620919 | pubmed:author | pubmed-author:ThompsonR CRC | lld:pubmed |
| pubmed-article:8620919 | pubmed:author | pubmed-author:MartinDD | lld:pubmed |
| pubmed-article:8620919 | pubmed:author | pubmed-author:RussellD ADA | lld:pubmed |
| pubmed-article:8620919 | pubmed:author | pubmed-author:ReltonJ KJK | lld:pubmed |
| pubmed-article:8620919 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8620919 | pubmed:volume | 138 | lld:pubmed |
| pubmed-article:8620919 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8620919 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8620919 | pubmed:pagination | 206-13 | lld:pubmed |
| pubmed-article:8620919 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:meshHeading | pubmed-meshheading:8620919-... | lld:pubmed |
| pubmed-article:8620919 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8620919 | pubmed:articleTitle | Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. | lld:pubmed |
| pubmed-article:8620919 | pubmed:affiliation | Department of Preclinical Pharmacology, Amgen Inc, Boulder, Colorado 80301, USA. | lld:pubmed |
| pubmed-article:8620919 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8620919 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8620919 | lld:pubmed |
